Seaport Therapeutics, Inc. — Form 10-Q
Filed November 2, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 12/100
What the filing says
This is Seaport Therapeutics' Q3 2026 quarterly report (period ending September 30, 2026) filed November 2, 2026. The filing metadata shows company assets of $441.7M and includes standard certifications and XBRL exhibits. The document itself was not provided in full text, so specific financial metrics, operational changes, clinical progress, or material transactions cannot be detailed.
Why this rating
Routine quarterly filing with no substance provided; absent actual 10-Q content, no material facts assessable.
See more from November 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.